To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Empasiprubart (ARGX-117) is an investigational, first-in-class, humanized recycling monoclonal antibody that targets complement component C2. By binding C2, it selectively inhibits the classical and lectin complement pathways, while preserving the alternative pathway, an important component of innate antimicrobial defense.
Empasiprubart has been engineered to have a long half-life through FcRn-mediated recycling and works through a unique pH- and calcium-dependent binding mechanism that promotes C2 clearance. Empasiprubart has the potential to reduce complement-driven inflammation and tissue damage in autoimmune and inflammatory diseases.
Current argenx Pipeline Progress
No results
Mechanism of Action
Empasiprubart is a novel, humanized, IgG1 monoclonal antibody (mAb) that binds to C2, thereby blocking downstream activation of both the classical and lectin complement pathways, while leaving the alternative pathway intact. Empasiprubart binds to C2 in a pH- and calcium-dependent manner and is engineered for increased affinity to FcRn at acidic pH to achieve a prolonged half-life.
- Empasiprubart binds to C2 in circulation before being internalized into the cell
- C2 is released in the endosome
- Empasiprubart binds to FcRn
- Unbound C2 is degraded in the lysosome
- Empasiprubart escapes lysosomal degradation and is recycled back into circulation
Publications
Explore the peer-reviewed publications behind the clinical development and outcomes of empasiprubart and more in long-overlooked diseases.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
ARGX-118
Designed around the first novel airway inflammation target identified in decades.
Efgartigimod
The science and data behind our first-in-class FcRn-targeting antibody for long-overlooked diseases.
Partnered Program Success
See how IIP-born assets move forward with the right partners.
